Dossier overview
4
research areas
3
references
3
handling notes
01
Mechanism of action
Ipamorelin binds the growth hormone secretagogue (GHS-R1a), the ghrelin receptor, to induce pulsatile growth hormone release. Early pharmacology characterised it as more selective than first-generation GHRPs.
02
Research applications
- Ghrelin / GHS-R1a pharmacology
- Rodent bone-growth and growth-hormone axis research
- Pharmacokinetic / pharmacodynamic modelling
- Comparative growth hormone secretagogue research
Evidence at a glance
What's behind this profile
3 citations · 1998–1999
- Human
- 1
- Animal
- 2
Studies in human volunteers or patients (incl. early-phase trials).
Studies in rodents or other animal models.
Publication years
- 98
- 99
Counts are derived from the cited studies below. A study covering both in vivo and in vitro work is counted by its primary model. Sample size is reported in 1 of 3 citations. Findings remain model-specific and are not extrapolated to therapeutic use.
03
Study references
Each profile cites a minimum of two peer-reviewed sources, with model type and reported sample size where the source provides it. Findings are model-specific and must not be extrapolated to therapeutic use.
Ipamorelin, the first selective growth hormone secretagogue
1998
Raun K et al. · European Journal of Endocrinology
- Model
- Preclinical pharmacology (in vitro receptor binding + in vivo rat and swine GH-release studies)
- Sample
- Not reported in abstract
Reported selective GH release versus , cortisol, and prolactin in animal models — establishing the selective-secretagogue profile that defined the compound.
Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats
1999
Johansen PB et al. · Growth Hormone & IGF Research
- Model
- In vivo — rats (15-day dose-ranging study)
- Sample
- Not reported in abstract
Dose-dependent increases in longitudinal bone growth and body weight in rats over 15 days of administration.
Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers
1999
Gobburu JV et al. · Pharmaceutical Research
- Model
- Phase I dose-escalation pharmacokinetic study in healthy male volunteers
- Sample
- n=40
Reported dose-proportional with a ~2-hour and episodic GH release after intravenous administration in healthy adult men.
Evidence caveats
- Ipamorelin is not approved as a medicine; the published human evidence is limited to early-phase pharmacokinetic studies (small cohorts, short duration).
- Subsequent development was discontinued at Phase II; long-term safety and efficacy in humans have not been established in peer-reviewed literature.
04
Storage and handling
Store under controlled laboratory conditions with batch and preparation details recorded.
- Maintain batch and supplier documentation for comparison studies.
- Record conditions and avoid repeated cycles where not protocol-supported.
- Research-only inventory must be clearly separated from any clinical material.